4883.T

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$800M	-61.0%	$-22.20	$-22.20–$-22.20	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$36.40

Price

$32.00

Implied upside

+14%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
4883.TModalis Therapeutics Corporation	$32.00	-3.03%	$3.1B	—
206A.TPRISM BioLab Co.,LTD	$161.00	-3.01%	$6.0B	—
2796.TPharmarise Holdings Corporation	$505.00	-0.39%	$5.8B	—
4539.TNippon Chemiphar Co., Ltd.	$1550.00	+0.00%	$5.6B	—
4576.TD. Western Therapeutics Institute, Inc.	$69.00	-20.69%	$4.0B	—
4582.TSymBio Pharmaceuticals Limited	$56.00	+0.00%	$3.1B	—
4586.TMedRx Co., Ltd	$61.00	+1.67%	$3.6B	—

Source: Financial Modeling Prep · peers by sector/industry

Modalis Therapeutics Corporation

Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.

modalistx.com

Employees: 17
IPO / List date: Aug 3, 2020
HQ: JP

Held by traders on TradeandTell

No one on the platform currently holds 4883.T.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 4883.T as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 4883.T yet.